VivoSeq
Metabolic & Endocrine

Overweight or Obesity

4

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Overweight or Obesity is an early-stage landscape with 4 programs across 4 companies. The most active players are Roche, Fujian Shengdi Pharmaceutical Co., Ltd., Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1F

Fujian Shengdi Pharmaceutical Co., Ltd.

2 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Regeneron logo

Regeneron

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSPeptide133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 50% of 6 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting3 · 50%
Not yet recruiting2 · 33%
Completed1 · 17%

Clinical Trials

Trial Activity

6 trials

A Randomized Control Trial to Improve Metabolic Outcomes in African American Pregnant Women
Recruiting·UUniversity of Illinois at Chicago·Preclinical·NCT05234125·150 enrolled
An Investigator- and Participant-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
Recruiting·Roche logoRoche·Phase 1·NCT07499050·30 enrolled
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity
Recruiting·Regeneron logoRegeneron·Phase 1·NCT07594093·90 enrolled
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Participants With Obesity
Not yet recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT07690826·252 enrolled
A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity
Not yet recruiting·Regeneron logoRegeneron·Phase 2·NCT07685808·360 enrolled
Sleep Extension or Regularity to Reduce Diabetes Risk
Completed·UUniversity of Chicago·Preclinical·NCT06128265·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)